Previous 10 | Next 10 |
Syndax Announces Presentation at Stifel 2020 Virtual Healthcare Conference PR Newswire WALTHAM, Mass., Nov. 11, 2020 WALTHAM, Mass. , Nov. 11, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage...
Syndax Pharmaceuticals to Present Updated Data from Phase 1 Trial of Axatilimab in cGVHD During Oral Session at the 62nd ASH Annual Meeting - Response rate of ~60% observed in patients following a median of five prior lines of treatment - - Company to host conference call an...
Kura Oncology (KURA) slumps 15% premarket on light volume in apparent reaction to the release on an abstract on leukemia candidate KO-539 that will be presented at the American Society of Hematology ((ASH)) Annual Meeting in early December.Preliminary results from the first three pa...
Syndax Pharmaceuticals, Inc. (SNDX) Q3 2020 Earnings Conference Call November 02, 2020, 16:30 ET Company Participants Melissa Forst - Argot Partners Briggs Morrison - CEO & Director Michael Metzger - President, COO & Director Daphne Karydas - CFO Conference Call Participants Philip Na...
Syndax Pharmaceuticals (SNDX): Q3 GAAP EPS of -$0.46 misses by $0.02.Revenue of $0.38M (flat Y/Y) misses by $0.02M.Q4 2020 Guidance: R&D expenses are expected to be $15-20M, and total operating expenses of $20-$25M.Press Release For further details see: Syndax Pharmaceutic...
Syndax Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Clinical and Business Update - Presentation of Phase 1 data from AUGMENT-101 trial of SNDX-5613 and initiation of Phase 2 on track for early 2021 - - Company provides update on axatilimab develo...
Syndax to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 2, 2020 PR Newswire WALTHAM, Mass., Oct. 26, 2020 WALTHAM, Mass. , Oct. 26, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or ...
Kronos Bio has filed proposed terms for a $175 million U.S. IPO. The firm is advancing a pipeline of treatment candidates for acute myeloid leukemia [AML] and solid tumors. KRON has shown intriguing early trial results and has a significant collaboration relationship with Gilead S...
Syndax Pharmaceuticals, Inc. (SNDX) Q2 2020 Earnings Conference Call August 6, 2020 16:30 ET Company Participants Melissa Forst - Senior Vice President, Argot Partners Briggs Morrison - Chief Executive Officer Daphne Karydas - Chief Financial Officer Conference Call Participan...
The following slide deck was published by Syndax Pharmaceuticals, Inc. in conjunction with their 2020 Q2 earnings Read more ...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
14.37%Change Percent:
Syndax Pharmaceuticals Inc. Company Name:
SNDX Stock Symbol:
NASDAQ Market:
Syndax Pharmaceuticals Inc. Website:
Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia PR Newswire – New PDUFA action date of December 26, 2024 allows FDA additional time to complete their review – WALTHAM, Mass. , ...
Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024 PR Newswire WALTHAM, Mass. , July 25, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing...
PALM BEACH, Fla., June 17, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Acute Myeloid Leukemia (AML) is a type of cancer that affects the blood and bone marrow. It is characterized by the rapid growth of abnormal myeloid cells, which are immature blood cells that normally...